August 27, 2018
SALT LAKE CITY, UT / ACCESSWIRE / August 27, 2018 / ProLung, Inc. (''ProLung'' or the ''Company'') today released a communication urging stockholders to fill out and return the GOLD consent revocation card from the Company, which they can use to decline or revoke consent to the actions proposed by
August 15, 2018
SALT LAKE CITY, UT / ACCESSWIRE / August 15, 2018 / ProLung, Inc. (“ProLung” or the “Company”) today released a communication urging stockholders not to respond to the consent solicitation by Steven C. Eror. The Company announced that stockholders will soon receive consent revocation materials and
June 18, 2018
SALT LAKE CITY, UT / ACCESSWIRE / June 18, 2018 / Corporate Vision announced that ProLung, Inc. ("ProLung" or the "Company") is their "2018's Most Innovative Predictive Analytics Award - USA" winner. Andy Robertson, Chief Marketing Officer of ProLung® stated, "Earning this innovation award is
May 30, 2018
ProLung is very excited to have our Company and product, the ProLung Test™, featured in Pharma Tech Outlook’s May 2018 Special Issue on Pharma Analytics. Named as a Top Ten Analytics Solution Provider in 2018, we are eager to continue preparing for commercialization and pursuing a bold strategy to
May 01, 2018
SALT LAKE CITY, UT / ACCESSWIRE / May 1, 2018 / Stoel Rives LLP and the Utah Technology Council (UTC) announced that ProLung, Inc. (''ProLung'' or the ''Company'') is their 2018 Utah Innovation Award winner for the ''Life Science - BioTech'' category. Steven Eror, President and CEO of ProLung®
April 30, 2018
ProLung is hoping to change the way lung cancer is detected through its test that measures the difference in conductivity between malignant and benign lung tissue. Courtesy of ProLung Three years ago, the U.S. Preventative Services Task Force and Centers for Medicare and Medicaid Services added
April 23, 2018
SALT LAKE CITY, UT / ACCESSWIRE / April 23, 2018 / Global Health and Pharma (GHP) announced that ProLung, Inc. (''ProLung'' or the ''Company'') is their 2018 Biotechnology Award winner for '' Best Medical Technology Company 2018 - USA and Best Lung Cancer Predictive Analytics Risk Testing Platform
April 02, 2018
ProLung is honored to be featured in a special issue of MedTech Strategist for innovative technologies and influential companies. As a “Start-Up to Watch”, ProLung CEO and co-founder, Steven C. Eror, shares the development behind ProLung’s solution to an unmet clinical need for lung cancer.
March 28, 2018
ProLung, Inc. is focused on making a difference in time for lung cancer patients with its innovative predictive analytics technology and non-invasive tests for the risk stratification of indeterminate pulmonary nodules. Today ProLung announces the appointment of Mark V. Anderson, CPA as Chief Financial Officer.
March 26, 2018
We are excited to announce our ProLung Test™ has been selected as a finalist in the Life Science-Biotech category for the 2018 Utah Innovation Awards, presented by Stoel Rives LLP and the Utah Technology Council! ProLung will be attending the Awards Dinner in Salt Lake City later this month.